By C. Simone Fishburn, Editor In Chief It’s still anyone’s guess as to how long the COVID-19 outbreak will take to peak, let alone wane...

By Manasi Vaidya, Reporter, New York Sodium-glucose cotransporter-2 (SGLT2) inhibitors’ growing prominence in diabetic kidney disease...

By Bernarda Tundzhay, Reporter, London Novavax’s (NASDAQ:NVAX) NanoFlu influenza vaccine has garnered lukewarm expert predictions for its...

By Selina Koch, Senior Editor After finally getting the message that they need to look beyond amyloid to treat Alzheimer’s disease,...

Novartis’ (SIX:NOVN) Zolgensma (onasemnogene abeparvovec-xioi) has strong potential to be used as a first-line treatment in spinal...

The reimbursement experience physicians are having with AbbVie’s (NYSE:ABBV) Orilissa (elagolix) in endometriosis-related pain is likely...

Aclaris Therapeutics’ (NASDAQ:ACRS) Phase II ATI-502 for alopecia areata (AA) and Phase II for ATI-501 for AA, alopecia universalis (AU)...

Aldeyra Therapeutics’ (NASDAQ:ALDX) focus on seasonal allergies in its Phase III study of reproxalap in allergic conjunctivitis has three...

Immunomedics’ (NASDAQ:IMMU) Phase I/ II sacituzumab govitecan hormone receptor positive (HR+) Her2-negative breast cancer data may not be...

Eisai’s (TYO:4523) Lenvima (lenvatinib) has a clear path to approval in first-line hepatocellular carcinoma (HCC), with its positive...